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Abstract 
Close to 12 million people living with Human Immunodeficiency Virus (HIV) infection were infected with 
syphilis in 2004. Most of these infections occurred in developing countries with sub-Saharan Africa and South 
East Asia dominating. The global efforts to tackle syphilis infection are mostly aimed at pregnant women yet 
such kind of localized interventions leave other susceptible individuals at risk of infection leaving great public 
and clinical impact.   
The aim of our study was to compare CD4 counts in HIV positive syphilis negative and syphilis positive Highly 
Active Antiretroviral therapy (HAART) naïve patients. The study was approved by Research and Ethic 
Committee and Institutional Review Committee of Mbarara University of Science and Technology. We 
recruited 212 HIV positive participants and blood samples were collected for CD4 count, Rapid Plasma Reagin 
(RPR) and Treponema Pallidum Haem Agglutination (TPHA) tests. The data was analyzed using STATA 12.0E 
(STATACORP LP TEXAS USA). 95% confidence level was used and where a predictor and outcome are 
compared, a p-value of < 0.05 was considered significant.  
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* Corresponding author.  
International Journal of Sciences: Basic and Applied Research (IJSBAR)(2017) Volume 31, No  2, pp 21-27 
22 
 
Our study recorded a high prevalence (11.3%, 95% CI: 9.2 – 14.8%) of syphilis in HIV HAART naïve patients.  
The current study reports lower CD4 count in syphilis positive HIV patients (mean 318/µl) compared to syphilis 
negative HV positive patients (mean 656/µl), p value < 0.0001. 
As a conclusion; there is high prevalence of syphilis – HIV co-infections in Uganda. Syphilitic HIV patients 
tends to have lower CD4 counts compared to non syphilitic HIV patients. 
Keywords: HIV; syphilis; CD4; HAART naïve; coinfection.  
1. Introduction  
There have been a rise in prevalence of syphilis in HIV positive individuals [1] with many unreported or 
undiagnosed cases [2]. This have created a public health concern as both diseases though transmitted in similar 
ways may expose affected individuals to devastating morbidity and mortality [3-4]. The global prevalence of 
HIV and syphilis co – infection have been rising [5] and developing countries are more affected [6-7]. An 
estimated 12 million HIV positive people were infected with syphilis in 2004 of which about 70% were in sub-
Saharan Africa and South East Asia [8-9]. The global efforts to tackle syphilis infection mostly aimed at 
pregnant women and such kind of localized interventions leave other susceptible individuals at risk of infection 
leaving syphilis to gain significant public and clinical impacts [10].Different countries show different 
seroprevalence of syphilis HIV co-infection, for example the prevalence varies from 5% in Thailand to 12.9% in 
Turkey [11-13]. Uganda have reported varied prevalence of HIV syphilis co-infection with some studies 
reporting up to 64.3% [14-18]. The course of syphilis infection in HIV-positive patients differ from that in HIV 
negative patients and is associated with an increase in viral load and reduction in CD4 cell count [19]. This 
precipitates the progression of HIV infection and can lead to early death in HIV patients.  In Uganda, syphilis is 
routinely screened only in pregnant women. This leaves other groups with danger of emerging syphilis 
prevalence. HIV positive individuals are not screened for syphilis unless they present with signs and symptoms 
of syphilis infection. This practice however leaves HIV patients to battle with many complications resulting 
from the deleterious effect of syphilis which would be easier. Syphilis will later if not treated in time accelerate 
progression of HIV infection to AIDS. Early diagnosis and treatment of syphilis in HIV patients may prevent 
infection-associated complications in most instances. Consequently, prevention of syphilis and other sexually 
transmitted diseases is of great importance for patients infected with HIV. The study therefore was conducted to 
establish the prevalence of HIV and syphilis co – infection and to compare CD4 levels in syphilitic and non 
syphilitic HIV patients.  
2. Methods 
The study was approved by Research and Ethic Committee and Institutional Review Committee of Mbarara 
University of Science and Technology. We recruited two hundred and twelve HIV positive males and females 
attending Makulubiita Health Centre III between March and July 2015. Questionnaires were used to collect 
demographic data. Ten (10) millitres of venous blood was collected from each consented participant into a plain 
vacutainer and EDTATM vacutainer (BD plain tubeTM, New Jersey USA). Blood in the plain vacutainers were 
allowed to clot for 30 minutes before serum could be separated. Blood in the EDTA was used for CD4 count. 
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The CD4 counts were measured using PIMATM machine (AlereTM, USA) following manufactures’ user manual 
and results reported in counts/ml of blood. Serum samples were screened for syphilis serostatus using RPR 
(Cypress diagnostics, Hulshout, Belgium) and all serum samples were subjected to confirmation using TPHA 
(Cypress diagnostics, Hulshout, Belgium) irrespective of the RPR result. The data was analyzed using STATA 
12.0E (STATACORP LP TEXAS USA). Chi square test was used to compare categorical variables and 
students’ t-test was used to compare continuous variables. 95% confidence level was used and where a predictor 
and outcome are compared, a p-value of < 0.05 was considered significant. 
3. Results 
We recruited 212 males and females aged between 18 and 70 years. The mean age of the participants was 38 
years with the mean age for males being 36 years (95% CI 30 – 41 years), the mean age for female participants 
was 39 years (95% CI 34 – 43 years). The smallest age of the participants was 19 years and the largest age was 
65 years.  
The general prevalence of syphilis (denoted as TPHA positive) was 24 (11.32%, 95% CI: 9.2 – 14.8%), table 
1.1 
Table 1.1: Syphilis serostatus (n=212) 
 RPR  TPHA P – value  
 Negative Positive Negative Positive  
Males  48 13 53 8 0.0356 
Females  131 20 135 16 
 
Table 1.2: Comparing RPR in syphilis screening (n=212) 
 
 
 
              Positive syphilis (TPHA positive) 
Yes No Total 
RPR positive  
24 
 
9 
 
33 
RPR negative 2 177 179 
Total 26 188 212 
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Sensitivity of RPR: 92%; Specificity of RPR: 94%. PPV: 72.7% and the NPV: 99% 
The mean CD4 count for syphilitic participants was 318/µl (95% CI 222 – 414/µl) and the mean CD4 count for 
non syphilitic participants was 656/µl (95% CI 611 – 700/µl), p value < 0.0001. However, the mean CD4 count 
of male participants was 509/µl (95% CI 461 – 557/µl) and that of female participants was 661/µl (95% CI 605 
– 718/µl) p value 0.0015. 
4. Discussion 
 In the last decade, patients with HIV infection have had an increased incidence of not only early syphilis but 
also other STDs, primarily due to a resurgence of high-risk sexual behaviours. A longitudinal study conducted 
among US military personnel found that 5.8% of 4239 newly diagnosed HIV infections also had serological 
evidence of syphilis infections [20]. Most countries including Uganda have not adopted screening for syphilis 
when testing for HIV or during HIV disease progression monitoring. This has left syphilis co infection in HIV 
unchecked yet there are profound medical and public health impact of this negligence. Our study recorded a 
high prevalence (11.3%) which was comparative to that of a cohort conducted in Mozambique where the 
prevalence of syphilis among HIV positive HARRT naïve individuals was 16.7% [21]. However, other studies 
have reported much higher seroprevalence of syphilis in HIV positive HARRT naïve individuals. A study in 
Ethiopia for example showed a seroprevalence of 38% [22] of HIV positive HAART naïve individuals (blood 
donors). Interactions between syphilis and HIV infection are not fully documented in HIV positive HAART 
naïve individuals. But several studies have found link between syphilis infection in HIV-positive individuals and 
reduced CD4 cell count [19, 23].  The current study found out that CD4 count was lower in syphilitic HIV 
patients (mean 318/µl) compared to non syphilitic HV patients (mean 656/µl). Several studies across the globe 
[24-27] found similar trend, yet this would mean HIV positive patients infected with syphilis will progress 
rapidly to AIDS (as a result of low CD4 count), a morbidity that will leave many of them suffering from 
constant opportunistic infections [28-29] and increases their mortality rate [30-31].  
5. Conclusion 
Syphilis co-infection with HIV is common among HIV positive patients in Uganda. Blood CD4 cell count is 
lower in syphilitic HIV positive patients compared to non syphilitic HIV patients. This means syphilis affect 
CD4 counts in HIV patients negatively. 
6. Recommendations 
Syphilis screening should be incorporated into the national HIV screening and testing program. Patients living 
positively with HIV should have mandatory routine syphilis screening for early diagnosis and treatment of the 
condition.  
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